About Retia Medical

Retia Medical is a venture-funded startup backed by the Pritzker-Vlock family office. Retia’s first product is a patient monitor (The Argos) for tracking cardiac output (blood flow rate). The initial interest for this technology is the ICU and operating rooms. Approximately 15 million surgical patients and 3 million intensive care patients worldwide could benefit from this technology. Based in Valhalla, NY, Retia’s technology was developed at Michigan State University and Massachusetts Institute of Technology and validated through extensive tests in animals and humans. With the support of a strong advisory board comprised of industry and clinical experts, Retia received FDA 510(k) clearance and launched this product in December 2018, which will help revolutionize the care of the most at-risk patients.